We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.15 | 3.85% | 4.05 | 573,877 | 11:00:04 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.90 | 4.20 | 4.05 | 3.90 | 3.90 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 3.19M | -6.49M | -0.0122 | -3.32 | 20.8M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 11:25:45 | O | 73,367 | 4.089 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/9/2024 | 13:15 | ALNC |  Eden Research half-year revenue surges nearly 75% despite rising costs |
| 23/9/2024 | 07:00 | UK RNS | Eden Research plc Half yearly Report |
| 20/9/2024 | 07:00 | UK RNS | Eden Research plc Notice of Results |
| 02/9/2024 | 07:00 | UK RNS | Eden Research plc Nematicide Approval in Greece |
| 15/8/2024 | 07:00 | UK RNS | Eden Research plc Appointment of new Head of Regulatory Affairs |
| 13/8/2024 | 14:16 | ALNC | Eden Research hails approval of biofungicide Mevalone in Germany |
| 13/8/2024 | 07:00 | UK RNS | Eden Research plc Biofungicide regulatory authorisation in Germany |
| 17/7/2024 | 07:00 | UK RNS | Eden Research plc Appointment of Global Product and Marketing Lead |
| 10/7/2024 | 10:12 | UK RNS | Eden Research plc Director/PDMR Shareholding |
| 05/7/2024 | 07:00 | UK RNS | Eden Research plc Grant of Awards Under Long-Term Incentive Plan |
Eden Research (EDEN) Share Charts1 Year Eden Research Chart |
|
1 Month Eden Research Chart |
Intraday Eden Research Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/10/2024 | 11:53 | Eden Research | 18,754 |
| 08/2/2024 | 07:42 | Eden....Onward and Upwards! | 52 |
| 21/6/2023 | 12:05 | The sterile garden of Eden | 123 |
| 29/3/2022 | 16:04 | Eden Research | 14 |
| 29/3/2022 | 14:36 | Eden Research - Who Is Behind Thallo Eco Products Corp? | 27 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-03 10:25:46 | 4.09 | 73,367 | 2,999.98 | O |
| 2024-10-03 10:00:28 | 4.20 | 59 | 2.48 | O |
| 2024-10-03 09:22:54 | 4.10 | 24 | 0.98 | O |
| 2024-10-03 08:27:06 | 4.08 | 121,658 | 4,963.65 | O |
| 2024-10-03 08:24:58 | 4.02 | 125,000 | 5,031.13 | O |
| Top Posts |
|---|
Posted at 03/10/2024 09:20 by Eden Research Daily Update Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 3.90p.Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £21,600,777. Eden Research has a price to earnings ratio (PE ratio) of -3.32. This morning EDEN shares opened at 3.90p |
Posted at 01/10/2024 16:54 by neutralpov Investingisatrickyga> Alchemy, > Management has publicly announced expected imminent news on slide 9 of the AGM presentation. > Management has said that in their opinion, the share price today should be north of the 20p price target from Cavendish. > Today, the shares are circa 4p. What's not to be confident about! * ARCHIVED * * ARCHIVED * * ARCHIVED * * ARCHIVED * Yeah, CONFIDENT that you are a paid ramping crook operating in blatant breach of s28 of FSMA 2000, s1 of the Fraud Act, etc. And that the parties you name are either delusional fools or - well, we know what. VERMIN. In my opinion, not enough eyes focusing on Eden and not enough eyes and ears reading and listening to Eden's communications. Viewing figures on filmed interviews might bear this out. As such, you might view 4p as a rare and wonderful buying opportunity, if you understand Eden. |
Posted at 01/10/2024 16:20 by investingisatrickygame Alchemy,Management has publicly announced expected imminent news on slide 9 of the AGM presentation. Management has said that in their opinion, the share price today should be north of the 20p price target from Cavendish. Today, the shares are circa 4p. What's not to be confident about! In my opinion, not enough eyes focusing on Eden and not enough eyes and ears reading and listening to Eden's communications. Viewing figures on filmed interviews might bear this out. As such, you might view 4p as a rare and wonderful buying opportunity, if you understand Eden. |
Posted at 25/9/2024 16:40 by investingisatrickygame If you refer to Eden's presentations and add up the aggregate sales per annum over each product at peak sales within 3 years from launch, they predict circa £130 million per annum. So if they were all at 3 years, purely for illustration, and had 10 years in front of them, possibly £1.3 billion or more in salesA regulatory approval can last 10-15 years as I understand it and of course, can be renewed. Eden has a large pipeline of opportunities, they say. The Chairman stated in the half yearly report, that 'the potential for Eden is huge' The CEO said 'We anticipate the remainder of the year will provide plenty of reasons for excitement' The CFO in the Q and A re-iterated that it takes around $300 million and 10-12 years to develop a successful pesticide, yet Eden has spent £20 million to get us to where we are today (4 products if we include our insecticide), thus offering significant additional profit opportunity as there is less cost to recover. Does any of this sound like a 4p per share company? I don't think so. Does any of this sound like a 20p per share company as per the Cavendish forecast? I don't think so. 50p a share values Eden at £267 million and Eden's gross margins as highlighted by the Company themselves, provide massive headroom to run the Company and return more than 50p a share. The regulatory approved footprint alone, in my opinion is already worth a lot of money, but 'the market' doesn't seem to have caught on with where Eden are OR Eden in its communications has not reached a sufficiently big wide enough audience in order to convince more people to realise the value already in Eden. |
Posted at 24/9/2024 13:19 by jaknife Money never sleeps,You are doomed to be a losing investor, like supersonico, who is already sitting on significant Eden losses. The basic maths (and the house broker) tells you that Eden is going to lose money for 2024 and 2025. Common sense should tell you that the share price of perpetually loss-making shares always heads to zero. The share price now is 4.05p (mid), let us discuss this again when the finals come out. JakNife |
Posted at 02/9/2024 11:15 by investingisatrickygame Another layer of value added to Eden Research Plc, not yet factored into the share price.Each regulatory (new or label extension) approval adds intrinsic value to Eden, even before sales begin. As sales accumulate thereafter, further value will be attributed. Why is there intrinsic value in Eden, purely from regulatory approval? In my opinion, that is because of the 8-10 year cycle for the likes of Syngenta to bring a successfully developed product to market, $300 million and whatever time during that period, a product has been off market and no revenue have been achieved. Even this does not factor in additional cost value for unsuccessful products and time and money spent on this. The ability to view a company like Eden with a significant geographical footprint for multiple products, where substantially less money has been spent and R & D time is in the past makes Eden an attractive investment proposition and an exciting to company to partner with. |
Posted at 15/8/2024 07:28 by supersonico Appointment of new Head of Regulatory AffairsEden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, is pleased to announce the appointment of Ilshad Moulan as the Company's new Head of Regulatory Affairs. Ilshad will bring his experience in the agrochemical sector to lead Eden Research's regulatory strategy and execution, helping to ensure the successful global registration of its innovative crop protection solutions. Ilshad has strong expertise in regulatory affairs management having led teams and managed complex projects across the industry. With a BSc degree in Biochemistry and Cell Biology and an MSc degree in Crop Protection and Regulatory Science, his strong scientific background complements his regulatory expertise. At Dr. Knoell Consult Ltd, Ilshad led a team of nine, focusing on regulatory affairs. His career began at Agrauxine, where he played a key role in developing dossiers for biopesticide active ingredients and formulated plant protection products. Additionally, his previous roles at Evergreen Garden Care and Battelle involved supporting and managing regulatory submissions for conventional active ingredients and formulated products. Ilshad Moulan commented: "I am thrilled to join Eden Research at such an exciting time. I look forward to using my regulatory expertise to support Eden's mission of delivering sustainable solutions to the agricultural sector and ensuring our products reach farmers worldwide as quickly and efficiently as possible." Ilshad will be based at Eden Research's headquarters in Oxfordshire and will begin his new role immediately. He succeeds Dr. Mike Carroll who will retire at the end of a handover period. Mike has served as Eden's first-ever regulatory leader and played a key role in not only establishing Eden's in-house regulatory capabilities, but in successfully expanding the regulatory authorisations for Eden's existing and new products. Sean Smith, CEO of Eden Research, added: "We are delighted to welcome Ilshad to our team. His extensive background in regulatory affairs, combined with his leadership skills, will be a tremendous asset as we continue to navigate the complex regulatory landscape and bring our sustainable biopesticide products to market. At the same time, we thank Mike for all of his contributions over the past four years. His experience and leadership have been helpful in propelling our business forward and expanding our geographical footprint, and we are grateful for all his contributions. We wish Mike all the best for a long, happy retirement." |
Posted at 29/7/2024 06:32 by supersonico MNS,Consider the following informal announcements and tell me where there is an RNS to account for the commercial dynamic of the 10-12 insecticide relationship/s? Annual Eden Insecticide / development update...2019- Jan 2024 15 January 2019; The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging. 14 January 2020 Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaineä encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture." 11 February 2021 Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients. 2nd March 2022 Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden. 10 January 2023 Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work. Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results. The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US. 22 January 2024 A number of potential commercial partners for Eden's insecticide product ran, between them, a large number of field trials in 2023 and, so far, these have produced encouraging results. Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results. The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US. Eden has now started commercial discussions with various potential partners to begin the evaluation of who to appoint as distribution partner for the insecticide product and shall update the market during 2024, as appropriate. .................... |
Posted at 27/7/2024 11:36 by investingisatrickygame Super,agreed, way better than projections. Maybe Institutions aren't paying attention, aren't listening or need an absolute confirmation. Who knows. Listening to Corteva, it seems to me we can reasonably expect strong revenue from Ecovelex in 2025 and beyond. This should provide all the working capital Eden needs moving forward and take Eden into profit in 2025. Ecovelex will be a milestone moment, that's for a sure and could in itself trigger strong investment in Eden's share price. It should certainly be a recognition point, an inflection point and I imagine S Smith will communicate it this way. I believe you are right about the insecticides. In 2020, Eden quoted numbers for one insecticide being twice the value of the numbers quoted for Ecovelex. It is on their website on the 2020 AGM Q and A. The combination of these two terrific achievements delivering products where by their own (and Corteva's) commentary, others products do not exist, will surely put Eden on the map, both for investors if they truly understand the significance of the same, but equally, the Ag input industry. A higher share price and commercial interest in Eden is only a matter of time and that time is very near. Regulatory news and insecticide distribution partner news are both anticipated in 2024, are they not? |
Posted at 22/7/2024 20:05 by investingisatrickygame What about the Regulatory approvals and their value in isolation pre-sales. What is that worth in the share price today?1) We normally hear about 18-24 months for regulatory approval 2) How many regulatory approvals do we have? 3) How many people hours are invested in creating a regulatory submission? 4) How much, on average, does each regulatory submission cost? 5) How much, on average, does a label extension submission cost? 6) We've been told that it takes 8-10 years and $300 million to produce a new pesticide Eden has said the shares are worth north of the Cavendish target of 20p and they are worth this today. Let's randomly pick 25p. That is £133 million market cap. Eden's latest turnover figures were £3.1 million and we made a loss, so forget applying a P/E ratio. So where is the £133 million value today? Know-how, IP, regulatory approvals, time employed! £133 million is $172 million $172 million is 57% of the value cost of bringing one new pesticide to market. £133 million, arguably, represents 3 products (Mevalone, Cedroz, Ecovelex), all of which are really in their infancy. $300 million is £232 million. That would represent a share price of 44p for one product. We have 3, soon to be 4 and with an insecticide label expansion as per the 2023 Placing RNS, one might argue, 5. Even before you start adding in profits to the accounts and applying a P/E ratio, I would say it is clear to see the value in Eden from know-how, IP, regulatory approvals and time employed. Given the time, know-how and cost to create one product, I'd say the big boys wouldn't baulk at paying a lot of money to buy Eden. |
Posted at 21/7/2024 14:59 by investingisatrickygame If you ask management, they will tell you that the addressable market is a moving feast from year to year. That to me, is understandable.Where are we today? We have two products, Mevalone and Cedroz, both with an increasing regulatory footprint, approvals and label extensions. Corteva usually refer in their videos to Ecovelex being their product. In commercial agreements that may not be so, but it is the way they position it. With no incumbent product in Europe (?) the addressable market will be 100% of what is available, will it not?! With a 15 year regulatory approval, when it comes along, that is an awful lot of revenue and profit for both Corteva and Eden. Add Sunflowers, (perhaps) and other geographies and there is no way Corteva is going to want to have anyone else have direct access to 'their' bird repellent, without them being the licensee or re-seller. I mention this because to me, when assessing shareholder value, I can look to Corteva, 15 years, bird repellent and be secure in my mind that this is worth many, many times today's share price. That alone would be a starting point for anyone, in due course, looking to make an offer for Eden. That alone makes Eden a profitable company and a potential bid target. I assume the insecticide will be an Eden product because they have developed it themselves, without an approach from another, as with Corteva, at least to the best of my knowledge. The insecticide will/should, be Eden's biggest opportunity in terms of sales revenue. Finally, last time I calculated, with the current shares in issue, £5 million profit was worth 28p a share on 30* earnings with nothing built in for the future. Alex Abrey recently said on film, that in management's opinion the shares are worth north of 20p today, thus exceeding the Cavendish 20p target. A £10 million profit on the same basis is 56p a share. I don't think we are too many steps away in execution or time to exceed both of these numbers. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
